Bohlmann M K, Hoellen F, Hunold P, David M
Department of Obstetrics and Gynaecology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck.
Clinic for Radiology and Nuclear Medicine, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck.
Geburtshilfe Frauenheilkd. 2014 Feb;74(2):139-145. doi: 10.1055/s-0033-1360311.
Laparoscopic myomectomy is regarded as the gold standard for women with symptomatic fibroids who wish to become pregnant. High-intensity focused ultrasound (HIFU or MRgFUS) ablation of uterine fibroids is also being discussed as a non-surgical, minimally invasive, therapeutic option. This review examines the available data on the impact of HIFU/MRgFUS on fertility and pregnancy, focusing particularly on potential direct side-effects of this type of intervention on ovaries, fallopian tubes and uterus and potential late effects on pregnancy and birth, based on the current literature. All pregnancies after HIFU/MRgFUS published to date (around 100 cases) were evaluated. The published case series suggest that HIFU/MRgFUS ablation has no impact on the rate of miscarriages or other obstetrical outcome parameters. Because no prospective studies exist which permit firm conclusions to be drawn on the impact of HIFU/MRgFUS on fertility and pregnancy outcome in women with symptomatic fibroids, this approach is currently only recommended for women with suspected fertility problems due to uterine fibroids who either decline surgery or who have an unacceptably high surgical risk.
腹腔镜子宫肌瘤切除术被视为有症状的肌瘤患者希望怀孕时的金标准。高强度聚焦超声(HIFU或MRgFUS)消融子宫肌瘤也作为一种非手术、微创的治疗选择被讨论。本综述基于当前文献,研究了关于HIFU/MRgFUS对生育力和妊娠影响的现有数据,特别关注此类干预对卵巢、输卵管和子宫的潜在直接副作用以及对妊娠和分娩的潜在远期影响。对迄今为止发表的HIFU/MRgFUS术后所有妊娠情况(约100例)进行了评估。已发表的病例系列表明,HIFU/MRgFUS消融对流产率或其他产科结局参数没有影响。由于目前尚无前瞻性研究能够就HIFU/MRgFUS对有症状肌瘤患者生育力和妊娠结局的影响得出确凿结论,因此目前仅推荐给因子宫肌瘤存在疑似生育问题、拒绝手术或手术风险高得无法接受的女性。